secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K/A
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001628280-25-039392
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion amends Q2 earnings; reports $82.4M revenue, first operating income of $7.1M
--------------------------------------------------------------------------------

- Net loss narrowed to $12.7M from $61.9M in Q2 2024; EPS loss $0.06 vs $0.33.
- U.S. net product revenue rose 42% Y/Y to $40.3M; total revenue grew 12% to $82.4M.
- Achieved $7.1M operating income, first quarter of positive operating income from ongoing ops.
- Reached ANDA settlements blocking generic bempedoic acid until 2040.
- Cash $86.1M at June 30; expects sustainable profitability starting Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025039392/0001628280-25-039392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025039392/espr-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-039392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer